PMPRB Cancellation of March 18th Policy Forum
The Patented Medicines Prices Review Board (PMPRB) has announced the cancellation of its Policy Forum expected to be held on March 18th, 2020 amid the evolving COVID-19 situation.
In order to provide stakeholders with an opportunity to convey information that may ... Read More
10
Mar2020
26
Feb2020
PDCI is pleased to inform you of the launch of its podcast series, Between the Lines. Between the Lines invites thought leaders and industry experts to share their insights about the trends and controversies that are shaping the pharmaceutical policy ... Read More
24
Feb2020
Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest.
Summary of New pCPA Activity Since ... Read More
14
Feb2020
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH website.
In this Pharmaceutical Reviews Update, CADTH made program updates ... Read More
13
Feb2020
Following the publication of the PMPRB Draft Guidelines on Nov 21, 2019, PDCI undertook an analysis to critically assess the impact of the PMPRB regulatory changes published in August 2019, as proposed to be implemented in the Draft Guidelines.
Top-Line Summary
The PMPRB regulatory changes and Draft ... Read More
29
Jan2020
PDCI is excited to announce the promotion of Andrea Lau to the position of Associate Director, HTA and Clinical Evaluation.
Andrea has been with PDCI for over 3 years, and in that time has been invaluable ... Read More
15
Jan2020
Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest.
Summary of New pCPA ... Read More
14
Jan2020
W. Neil Palmer
In its December 2019 NEWSletter[1], the Patented Medicine Prices Review Board (PMPRB) is “reminding” patentees that they are required under the Patent Act (the Act) and the Patented Medicines Regulations (the Regulations) to file all zero-dollar sales, referring specifically to free goods. This “reminder” is troubling ... Read More
13
Jan2020
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH website.
CADTH released new updates to economic Category 1 Requirements ... Read More